BMS: Delayed new drug to avoid paying billions?
World of DTC Marketing
FEBRUARY 25, 2022
billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019. Food and Drug Administration approval for the non-Hodgkin lymphoma drug by a Dec. The post BMS: Delayed new drug to avoid paying billions?
Let's personalize your content